Northern Trust
GLMD icon

Northern Trust’s Galmed Pharmaceuticals GLMD Stock Holding History

Northern Trust’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-68
Closed -$83K – 4244
2018
Q4 		$83K Buy
68
+10
+17% +$17.5K ﹤0.01% 3962
2018
Q3 		$142K Buy
+58
New +$136K ﹤0.01% 3948

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Northern Trust's GLMD Position: Q1 2019 in Review

Northern Trust sold out of Galmed Pharmaceuticals (GLMD) in Q1 2019, closing a stake of 68 shares — an estimated $83K sold.

Northern Trust first reported a position in GLMD in Q3 2018 and held it in 2 quarters. The position peaked at $142K in Q3 2018. 34 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

  • Northern Trust reported no remaining Galmed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Northern Trust sold 68 Galmed Pharmaceuticals shares in Q1 2019, an estimated $83K.
  • Northern Trust first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Northern Trust's Galmed Pharmaceuticals position peaked at $142K in Q3 2018.
  • 34 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on Northern Trust's 13F filing for Q1 2019, filed 13 May 2019.